Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced inducement grants for newly hired employees. The Compensation Committee approved non-qualified stock options to purchase 42,300 shares on August 12, 2025.

The grants, issued under Aligos' 2024 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. The exercise price equals the closing price of Aligos' common stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are exclusively for new hires.

Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing in its Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection treatment. The study will evaluate 200 untreated subjects over 48 weeks, comparing ALG-000184 monotherapy to tenofovir disoproxil fumarate.

The randomized, double-blind study will assess both HBeAg+ and HBeAg- adult subjects, with primary endpoints focusing on HBV DNA levels. The trial will also evaluate safety, pharmacokinetics, and various biomarkers. Interim data is expected in 2026, with topline results anticipated in 2027.

Aligos Therapeutics (Nasdaq: ALGS) reported Q2 2025 progress and financial results, highlighting significant advancements in their liver and viral disease pipeline. The company's lead candidate, ALG-000184, is initiating Phase 2 B-SUPREME study for chronic HBV infection across multiple countries, with dosing expected to commence shortly. The Phase 1 study showed promising 96-week data with 100% of subjects achieving HBV DNA suppression.

The company reported positive Phase 2a HERALD data for ALG-055009, their MASH treatment candidate, demonstrating significant liver fat reduction and improvements in atherogenic lipids. Financial position remains strong with $122.9 million in cash as of June 30, 2025, providing runway into second half of 2026. Q2 2025 resulted in a net loss of $15.9 million, with R&D expenses at $14.0 million and G&A expenses at $5.6 million.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease therapies, has scheduled its Q2 2025 financial results announcement for Wednesday, August 6, 2025. The results will be released after U.S. financial markets close.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 2,100 shares on July 8, 2025.

The grants, made under Aligos' 2024 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The exercise price equals the closing price of Aligos' common stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are exclusively for new hires.

Aligos Therapeutics (ALGS) has appointed Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. Dr. Wesson brings over 20 years of pharmaceutical development experience to Aligos, having previously served at Kezar Life Sciences and AN2 Therapeutics. His notable achievements include leading drug substance development at Anacor Pharmaceuticals, where he supported the approval and commercial launches of Kerydin and Eucrisa. Dr. Wesson holds a PhD in Organic Chemistry from the University of Cambridge. The appointment comes as Aligos prepares to begin Phase 2 study of ALG-000184 in mid-2025.

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced the granting of inducement stock options to new employees. The Compensation Committee approved non-qualified stock options to purchase 26,000 shares, granted on June 10, 2025, under the company's 2024 Inducement Plan. These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price matching Aligos' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on continued employment.

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on Thursday, June 5, 2025, at 2:00 PM ET. Interested parties can access the live webcast through the Presentation & Events section of Aligos' investor relations webpage. A replay will remain available for at least 30 days following the presentation.

Aligos Therapeutics (Nasdaq: ALGS) has appointed Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries. She most recently served as Vice President, Corporate Law & Privacy Officer at Codexis. Her previous roles include being an independent legal consultant for companies like Genentech and Elan Pharmaceuticals, and serving as Practice Group Leader for BioOncology Development Law at Genentech.

The appointment was announced by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos, who emphasized Kavanaugh's extensive knowledge and broad expertise in legal matters. Kavanaugh holds a BA from UC Berkeley and a JD from Santa Clara University Law School.